3.09%
6.57%
-7.42%
-31.00%
-27.71%
47.02%
-61.41%
AI Spotlight on URGN
Company Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases.It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer.
It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer.The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc.to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer.
UroGen Pharma Ltd.was incorporated in 2004 and is based in Princeton, New Jersey.
Market Data
| Last Price | 11.35 |
| Change Percentage | 3.09% |
| Open | 11.24 |
| Previous Close | 11.01 |
| Market Cap ( Millions) | 479 |
| Volume | 302713 |
| Year High | 20.7 |
| Year Low | 9.78 |
| M A 50 | 11.2 |
| M A 200 | 13.4 |
Financial Ratios
| FCF Yield | -20.13% |
| Dividend Yield | 0.00% |
| ROE | 932.03% |
| Debt / Equity | 477.84% |
| Net Debt / EBIDTA | 3.74% |
| Price To Book | 19.17 |
| Price Earnings Ratio | -4.24 |
| Price To FCF | -4.97 |
| Price To sales | 5.36 |
| EV / EBITDA | -5.94 |
News
- Dec -02 - Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade
- Nov -13 - UroGen Pharma: Choice Based On Near Term High Value PDUFA
- Nov -06 - UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript
- Nov -06 - Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates
- Nov -05 - UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
- Aug -13 - UroGen Pharma Ltd. (URGN) Q2 2024 Earnings Call Transcript
- Aug -13 - Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates
- Aug -02 - Does Urogen Pharma (URGN) Have the Potential to Rally 171.05% as Wall Street Analysts Expect?
- Aug -01 - Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
- Jul -17 - Wall Street Analysts See a 149.01% Upside in Urogen Pharma (URGN): Can the Stock Really Move This High?
- Jun -17 - UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
- Jun -13 - Uber Advertising Announces Exclusive Partnership with T-Mobile Advertising Solutions
- Jun -13 - AscellaHealth Chairman and President Bill Oldham Named 2024 Philadelphia Titan 100
- Jun -06 - UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
- May -13 - UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript
- May -05 - New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
- May -04 - UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
- Apr -15 - UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
- Mar -15 - UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript
- Mar -14 - Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> RTGel Reverse-Thermal Hydrogel
Expected Growth : 9.27 %
What the company do ?
RTGel Reverse-Thermal Hydrogel is a novel, proprietary, and biocompatible hydrogel technology from UroGen Pharma Ltd. that reversibly changes its solubility in response to temperature changes.
Why we expect these perspectives ?
RTGel's 9.27% growth is driven by increasing adoption in urology clinics, expanding treatment of non-muscle invasive bladder cancer, and growing demand for minimally invasive therapies. Additionally, UroGen Pharma's strategic partnerships and investments in clinical trials have enhanced product visibility and accessibility, contributing to the segment's growth.
Urogen Pharma Ltd. Products
| Product Range | What is it ? |
|---|---|
| Jelmyto | Jelmyto is a mitomycin gel for urinary tract infection treatment. It is a sterile, gel-like formulation of mitomycin, an antibiotic, for intravesical use. |
| UGN-102 | UGN-102 is a mitomycin gel for the treatment of low-grade non-muscle invasive bladder cancer (LG-NMIBC). |
| RTGel | RTGel is a reverse thermal gelation technology for the sustained release of therapeutic agents in the bladder. |
UroGen Pharma Ltd.'s Porter Forces
Threat Of Substitutes
UroGen Pharma Ltd. has a unique product portfolio, which reduces the threat of substitutes. The company's focus on uro-oncology and uro-urology provides a competitive advantage, making it difficult for substitutes to enter the market.
Bargaining Power Of Customers
UroGen Pharma Ltd. has a diverse customer base, including hospitals, clinics, and patients. While customers have some bargaining power, the company's strong relationships and customer service mitigate this threat.
Bargaining Power Of Suppliers
UroGen Pharma Ltd. has a diversified supplier base, which reduces dependence on individual suppliers. The company's strong relationships with suppliers and its ability to negotiate prices mitigate the bargaining power of suppliers.
Threat Of New Entrants
The biotechnology industry is highly competitive, and new entrants can easily enter the market. UroGen Pharma Ltd. faces a high threat of new entrants, which could lead to increased competition and reduced market share.
Intensity Of Rivalry
The biotechnology industry is highly competitive, and UroGen Pharma Ltd. faces intense rivalry from established companies. The company must continuously innovate and improve its products to maintain its market position.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 290.91% |
| Debt Cost | 9.37% |
| Equity Weight | -190.91% |
| Equity Cost | 9.37% |
| WACC | 9.37% |
| Leverage | -152.38% |
UroGen Pharma Ltd. : Quality Control
UroGen Pharma Ltd. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CTMX | CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The … |
| AKBA | Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral … |
| MDXG | MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts … |
| LQDA | Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of … |
| ARMP | Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Akebia Therapeutics
A-Score
1-Year Total Return ->
🥈
MiMedx
A-Score
1-Year Total Return ->
🥉
CytomX Therapeutics
A-Score
1-Year Total Return ->
4
Armata Pharmaceuticals
A-Score
1-Year Total Return ->
5
UroGen Pharma
A-Score
1-Year Total Return ->
6
